Experiences with
Rituxan429 public posts
Want to take advantage of all our features? Just log in!
or
Chemo-free treatment with acalabrutinib can benefit CLL/SLL patients never treated before: a plain language summary of the ELEVATE-TN study
It has proven slightly superior to the first generation anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera), which was developed in the 1980s and approved for human use in 1997.
Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor. (BRUIN CLL-321 Phase III trial results reported at ASH2024)
[/i]
[i]Median progression-free survival (PFS) reached 14 months with pirtobrutinib, an oral non-covalent BTK inhibitor, as compared with 8.7 months with investigator's choice of idelalisib (Zydelig) plus rituximab (Rituxan) or bendamustine (Bendeka, Treanda) plus rituximab (HR 0.54, 95% CI 0.39-0.75